|Wednesday, 6 June 2018, 11:16 HKT/SGT|
TOKYO, June 6, 2018 - (JCN Newswire) - Eisai Co., Ltd. and Purdue Pharma L.P. presented the results of two key Phase I clinical studies (Study 108 and Study 106) of their investigational sleep/wake regulation agent lemborexant at the 32nd Annual Meeting of the Associated Professional Sleep Societies (SLEEP 2018), from June 2 to 6 in Baltimore, Maryland, the United States.
Lemborexant is currently being studied for the potential treatment of multiple sleep disorders. Positive topline results from these Phase I studies as well as a Phase III study (SUNRISE 1), which compared lemborexant to placebo in patients with a sleep disorder and included the first-ever head-to-head superiority comparison versus zolpidem extended release (zolpidem ER) as a secondary endpoint, were previously announced.
Phase I Study 108 - "Auditory Awakening Threshold to Evaluate Ability to Awaken After Administration of Lemborexant Versus Zolpidem" (Poster # 097)
Study 108 met its primary endpoint resulting in a statistically significant difference in postural stability with both doses of lemborexant compared to zolpidem ER in the middle of the night. The mean changes from baseline in body sway, a measure of postural stability, were -1.1 units for placebo, 5.8 units for lemborexant 5 mg, 8.1 units for lemborexant 10 mg, and 20.4 units for zolpidem ER 6.25 mg; (p<0.0001 vs. zolpidem ER for both lemborexant 5 mg and 10 mg).
Healthy volunteers 55 years and older (n=56) were administered treatments at bedtime, and body sway was assessed upon awakening participants after approximately four hours in bed. A 7 unit increase from baseline was defined as a clinically meaningful increase in body sway, as benchmarked to the effect of alcohol on the same measure of postural stability.(1) Zolpidem ER increased body sway at a magnitude almost three times greater than the increase in body sway associated with a blood alcohol content (BAC 0.05 percent) near the legal driving limit. Lemborexant 5 mg did not result in a clinically meaningful increase in body sway, while lemborexant 10 mg increased body sway to just above the clinically meaningful threshold.
The next morning, shortly after the end of eight hours in bed, unlike zolpidem ER, neither dose of lemborexant had statistically significant residual effects on this measure of postural stability as compared to placebo. The mean changes from baseline in body sway were -2.2 units for placebo, 0.4 units for lemborexant 5 mg, -0.4 units for lemborexant 10 mg, and 5.0 units for zolpidem ER 6.25 mg (p=NS [not significant] for both doses of lemborexant vs. placebo, p=0.01 for zolpidem ER vs. placebo).
"Postural instability is thought to be the single best predictor of falls.(2) Significant unmet need exists for a treatment that can help people awaken in the night or the next morning without this type of impairment," said Lynn Kramer, MD, Chief Clinical Officer and Chief Medical Officer, Neurology Business Group, Eisai. "If approved, lemborexant, our investigational sleep/wake regulation agent, may have the potential to reduce the risk of postural instability."
In this Phase I study, there were no serious adverse events (AE). Headache was the only AE observed in two or more subjects taking lemborexant. The only AE that occurred in more than one subject in any treatment period was nasopharyngitis, which occurred in the placebo treatment period. Rates of treatment-emergent AEs were low and of mild or moderate severity.
Two subjects discontinued due to an AE. There were no AEs of somnolence.
A secondary study objective was to evaluate the effects of lemborexant 5 mg and 10 mg on the auditory awakening threshold (AAT), a measure of the ability to be awakened by an external stimulus at approximately four hours post-dose, compared to zolpidem ER and placebo. A clinically meaningful increase in AAT was pre-specified as an 8-decibel (dB) change from baseline. Neither dose of lemborexant had a statistically significant difference relative to placebo or zolpidem ER on the ability to awaken to an external stimulus. The mean treatment differences compared to placebo were 1.7 dB for lemborexant 5 mg, -0.9 dB for lemborexant 10 mg, and 7.2 dB for zolpidem ER 6.25 mg (p=NS). Of the subjects who completed all four treatments, eight subjects taking zolpidem ER did not awaken to the loudest tone of 105 dB, compared with four subjects in each of the other treatment groups (placebo, n=42; lemborexant 5 mg, n=47; lemborexant 10 mg, n=50; and zolpidem ER, n=50). Varying n's were due to either the subject already being awake thus no AAT was administered, or a technical issue with the AAT equipment.
"By acting on the orexin neurotransmitter system, which regulates wakefulness, lemborexant appears to affect sleep and wake by dampening excessive wakefulness and does not appear to impede the ability to awaken to external stimuli," said Russell Rosenberg, PhD, D. ABSM, a Principal Investigator in lemborexant studies and former Chairman of the Board of the National Sleep Foundation. "As the largest study conducted to date evaluating postural stability and auditory awakening threshold in the middle of the night, these data about the effects of lemborexant on measures of balance and responsiveness to external stimuli are encouraging with respect to addressing current unmet needs in the treatment of sleep disorders."
In addition, return to sleep latency was evaluated as an exploratory endpoint and both doses of lemborexant had faster return to sleep after being awakened in the middle of the night compared to placebo. The mean treatment differences compared to placebo were -22.5 minutes for lemborexant 5 mg, -28.7 minutes for lemborexant 10 mg, and -21.0 minutes for zolpidem ER (p<0.0001 for all treatment groups compared to placebo). Lemborexant 10 mg also facilitated the return to sleep faster than zolpidem ER 6.25 mg (p=0.02).
These results support findings from SUNRISE 1, a recently completed Phase III study of lemborexant (5 mg and 10 mg) versus placebo, including a superiority comparison to zolpidem ER as a secondary endpoint. The study met endpoints of time to sleep onset and sleep maintenance as measured by polysomnography, as well as body sway upon awakening, when compared to placebo and zolpidem ER. In this study, lemborexant had rates of discontinuation due to AEs comparable to placebo, with the most common AEs in the lemborexant arms being headache and somnolence.
Phase I Study 106 - "Results From an On-Road Driving Performance Study in Non-elderly and Elderly Healthy Subjects with Dual Orexin Receptor Antagonist Lemborexant" (Poster # 099)
Study 106 evaluated next-morning effects of lemborexant compared with placebo, with zopiclone included as a positive control, by measuring adult and elderly participants' (n=48) driving performance via an on-road driving test. The primary endpoint was to evaluate difference from placebo of standard deviation of lateral position (SDLP), an index of weaving, during an on-road driving test on the mornings following the first and last dose of drug in each treatment period. Drug-placebo differences in SDLP >2.4 cm are considered to reflect clinically meaningful driving impairment, as benchmarked against a BAC of 0.05 percent.
Lemborexant 2.5, 5 and 10 mg showed no statistically significant impairment of driving performance, as measured by mean changes in SDLP, after either single (Day 2) or multiple (Day 9) dose administration compared to placebo, meeting the study's primary endpoint. In contrast, zopiclone 7.5 mg significantly increased mean SDLP as compared to placebo. The mean drug-placebo changes in SDLP (in centimeters) compared to placebo for Day 2 were 0.02 cm for lemborexant 2.5 mg, 0.23 cm for lemborexant 5 mg, 0.73 cm for lemborexant 10 mg, and 2.04 cm for zopiclone 7.5 mg. For Day 9, the mean drug-placebo changes in SDLP were 0.48 cm for lemborexant 2.5 mg, 0.36 cm for lemborexant 5 mg, 0.74 cm for lemborexant 10 mg, and 1.88 cm for zopiclone 7.5 mg. The upper bound of the 95 percent confidence intervals for the mean changes in SDLP were all below 2.4 cm for all three doses of lemborexant on Days 2 and 9, indicating that there was not clinically meaningful driving impairment. The upper bound of the 95 percent confidence intervals for the mean changes in SDLP for zopiclone was greater than 2.4 cm on Days 2 and 9, demonstrating assay sensitivity.
No drives were stopped before completion in the lemborexant treatment groups, whereas, three drives out of a total of 384 (0.8 percent) were terminated before scheduled completion, all after the use of zopiclone. No serious or severe AEs were reported in any treatment group. There were no treatment-related AEs leading to withdrawal from the study. The most common AEs observed in the lemborexant treatment groups were somnolence, headache, and dry mouth. Somnolence was reported more frequently with lemborexant 10 mg than lemborexant 2.5 mg and 5 mg.
"Sleep medications should not only improve the ability to sleep through the night, but also allow patients to awaken in the middle of the night, if needed, and to function upon awakening," said Marcelo Bigal, MD, PhD, Chief Medical Officer, Purdue Pharma. "We are pleased to share these study results and are committed to exploring the value of lemborexant in specific unmet needs of patients with sleep disorders."
Discovered by Eisai, lemborexant is a sleep/wake regulation agent being jointly developed by Eisai and Purdue. Through research and development on lemborexant, Eisai and Purdue are striving to improve the quality of life of, and further contribute to, sleep disorder patients and their families.
Lemborexant (development code: E2006), a dual orexin receptor antagonist, is Eisai's in-house discovered and developed small molecule compound that inhibits orexin neurotransmission by binding competitively to the two subtypes of orexin receptors (orexin receptor 1 and 2). In individuals with sleep disorders, it is possible that the orexin system that regulates sleep and wakefulness is not functioning normally. During normal periods of sleep, orexin system activity is suppressed, suggesting it is possible to purposefully counteract inappropriate wakefulness and facilitate the initiation and maintenance of sleep by interfering with orexin neurotransmission. Therefore, Eisai and Purdue have been developing lemborexant as a treatment for multiple sleep disorders.
In addition, a Phase II clinical study of lemborexant in patients with irregular sleep-wake rhythm disorder (ISWRD) and mild to moderate Alzheimer's dementia is underway.
About Study 1083
Study 108 was a randomized, double-blind, four-period, Phase I crossover study that evaluated the effect of lemborexant on postural stability, auditory awakening threshold and cognitive performance in healthy volunteers age 55 years and older; 120 subjects were screened, 63 randomized, and 56 completed all four treatment groups. Participants were administered a single dose of placebo, lemborexant 5 mg, lemborexant 10 mg, or zolpidem ER 6.25 mg, and had eight-hour polysomnograms at baseline and at each single-dose treatment. If not already awake, subjects were awakened, preferentially from stage non-REM 2 in the middle of the night (between four and four and a half hours post-bedtime/post-dose). At bedside, body sway with eyes closed was measured in units of 1/3o angle of arc for 60 seconds using an ataxiameter device. Increases from baseline of greater than or equal to 7 units were pre-specified as clinically meaningful, benchmarked to effect of alcohol at 0.5g/kg. At eight hours post-dose, body sway was assessed in the same manner.
The study also evaluated the effects of lemborexant on the AAT. Subjects slept with insert earphones, an auditory stimulus apparatus that produced 1000Hz tones for three seconds at 15-second intervals. The starting dB level was 15, increasing five dB to a maximum of 105dB, until the subject stated, "I'm awake." The awakening threshold was the dB level one level below the response.
About Study 1064
Study 106 was a randomized, double-blind, placebo- and active-controlled, four-period, Phase I crossover study evaluated the effect of lemborexant in 48 healthy adult and elderly volunteers to evaluate on-road driving performance. Participants (n=24 elderly and n=24 non-elderly) were treated at bedtime with two out of three dose levels of lemborexant (2.5, 5 or 10 mg) and placebo for eight consecutive days, and zopiclone 7.5 mg as an active control on days one and eight only, with placebo given for the six days in between. Standardized one-hour on-road driving tests on the second and ninth days were started approximately nine hours post-dose.
About Sleep Disorders
Population studies show that sleep disorders affect many more people worldwide than previously thought. Insomnia disorder is characterized by difficulty falling sleep, staying asleep or both, despite an adequate opportunity to sleep, that can lead to daytime consequences such as fatigue, difficulty concentrating and irritability.(4),(5) Insomnia disorder is the most common sleep disorder, with persistent insomnia symptoms experienced by approximately 10 percent of the adult population.(5),(6)
Sleeping well is essential for good health, including brain health. Poor sleep is associated with a wide range of health consequences, including an increased risk of hypertension, accidental injury, diabetes, obesity, depression, heart attack, stroke and dementia, as well as adverse effects on mood and behavior.(7),(8)
Experimental studies in animals and humans provide evidence of associations between sleep and disease risk factors, diseases and mortality.(5),(9) Studies suggest an optimal sleep duration between seven and eight hours.(5),(9) Women are 1.4 times more likely than men to suffer from insomnia.(10)
Older adults also have higher prevalence of insomnia; aging is often accompanied by changes in sleep patterns, including disrupted sleep, frequent waking and early waking, that can lead to less sleep time.)11)
About Purdue Pharma L.P.
Purdue Pharma L.P. is a privately held pharmaceutical company headquartered in Stamford, Conn. Purdue Pharma is part of a network of independent associated companies dedicated to providing patients and providers with innovative medicines. The company's leadership and employees are committed to serving healthcare professionals, patients and caregivers by providing quality products and educational resources that make a positive impact on healthcare - and on lives.
For more information, please visit www.purduepharma.com.
(1) Wesnes KA, Garatt C, Wickens M, Gudgoen A, Oliver S. Effects of sibutramine alone and with alcohol on cognitive function in healthy volunteers. Br J Clin Pharmacol. 2000;49:110-17.
(2) Blaszczyk JW, et al. Ageing and postural stability. Stud Phys Cult Tourism. 2006;13(S):11-14.
(3) Eisai Inc. Crossover study to evaluate the effect of lemborexant versus placebo and zolpidem on postural stability, auditory awakening threshold, and cognitive performance in healthy subjects 55 years and older (E2006-A001-108).
(4) Eisai Inc. Study to evaluate the effect of lemborexant versus placebo on driving performance in healthy adult and elderly subjects (E2006-E044-106).
(5) Ferrie JE, et al. Sleep epidemiology - a rapidly growing field. Int J Epidemiol. 2011;40(6):1431-1437.
(6) Ohayon MM, et al. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev. 002;6(2):97-111.
(7) Institute of Medicine. Sleep disorders and sleep deprivation: An unmet public health problem. Washington, DC: National Academies Press. 2006.
(8) Pase MP, Himali JJ, Grima NA, et al. Sleep architecture and the risk of incident dementia in the community. Neurology. 2017;89(12):1244-1250.
(9) Trenell MI, et al. Sleep and metabolic control: waking to a problem? Clin Exp Pharmacol Physiol. 2007;34:1-9.
(10) Zhang B, Wing, YK. Sex differences in insomnia: a meta-analysis. Sleep. 2006;29(1):85-93.
(11) Ohayon MM, et al. Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals: developing normative sleep values across the human lifespan. Sleep. 2004;27:1255-1273.
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Oncology and Neurology.
As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.
For more information about Eisai Co., Ltd., please visit www.eisai.com.
Purdue Pharma L.P.
Eisai Co., Ltd.
Public Relations Department
June 6, 2018 11:16 HKT/SGT
Eisai (TSE: 4523)
Topic: Press release summary
From the Asia Corporate News Network
Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|Jan 18, 2019 13:33 HKT/SGT|
Eisai's Notification Regarding Results of Voluntary Retirement Program|
|Jan 15, 2019 13:31 HKT/SGT|
Eisai to Present Results of Post-Hoc Analyses of Lenvima (Lenvatinib) Phase III Reflect Study in Hepatocellular Carcinoma at 2019 Gastrointestinal Cancers Symposium|
|Jan 15, 2019 13:23 HKT/SGT|
Eisai's New Drug Application for Insomnia Disorder Treatment Lemborexant Submitted in the United States|
|Jan 4, 2019 11:18 HKT/SGT|
Eisai's Etak Antimicrobial Spray Alpha Wins Nikkei Business Daily Awards for Superiority at the 2018 Nikkei Superior Products and Services Awards|
|Jan 4, 2019 08:39 HKT/SGT|
Eisai's New Drug Application for Perampanel Designated for Priority Review by China National Medical Products Administration |
|Dec 18, 2018 10:38 HKT/SGT|
Eisai: Bristol-Myers Squibb and H3 Biomedicine Announce Research Collaboration to Advance Novel Therapeutics Leveraging H3's RNA Splicing Platform|
|Dec 17, 2018 08:21 HKT/SGT|
Eisai Signs Collaboration Agreement for Anti-Obesity Agent Lorcaserin in Brazil with Eurofarma |
|Dec 12, 2018 09:06 HKT/SGT|
GARDP, Eisai and Takeda Announce Partnership in the Search for New Antibiotics|
|Dec 6, 2018 09:24 HKT/SGT|
Eisai and UCL Commence Preparations for Phase I Clinical Studies in Alzheimer's Disease for Novel Anti-Tau Antibody E2814 Discovered Through Joint Research|
|Nov 29, 2018 13:48 HKT/SGT|
Eisai: MOVICOL Launched in Japan|
|More news >>|